Takeda Pharmaceutical Company Limited

Taisuke Tawaraishi

Satoshi Yamamoto

Masaki Seto

Yasufumi Wada

Masato Yoshikawa

Minoru Nakamura

Shinji Nakamura

Tsuneo Oda

Makoto Kamata

Norihito Tokunaga

Kazuaki Takami

Yuya Oguro

Masaki Daini

Masahiro Kajino

Masataka Murakami

Shigemitsu Matsumoto

Mitsuhiro Ito

Satoshi Mikami

Shinji Morimoto

Yusuke Sasaki

Taku Kamei

Akito Shibuya

Kouichi Iwanaga

Jumpei Aida

Michiyo Mochizuki

Zenyu Shiokawa

Morihisa Saitoh

Paul D Greenspan

Takeshi Wakabayashi

Yusuke Tominari

Tomohiro Seki

Brian Scott Freeze

Haruhide Kimura

Yutaka Nakayama

Kosuke Hidaka

Yoshihisa Nakada

Yayoi Nakayama

Yasuo Nakagawa

Shumpei Murata

Akira Kawada

Taisuke Kato

Atsutoshi Okabe

Sachie Takashima

Hiroyuki Kakei

Shuji Hinuma

Naoyuki Kanzaki

Masanori Okaniwa

Fumio Itoh

Yuji Ishichi

Yuji Kawamata

Yayoi Yoshitomi

Mariko Hirohashi

The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

Methods of making a cyclic dinucleotide

The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

Heterocyclic compound and use thereof

Antibody-drug conjugates comprising a cyclic dinucleotide

This invention provides a compound represented by the formula (I): wherein Ris a hydrogen atom, a halogen atom, hydroxy, nitro, optionally halogenated alkyl, alkoxy optionally having substituents, acyl or amino optionally having substituents;Ris pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each of which may have substituents;n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I), which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating disease, bone and articular disease, kidney disease, liver disease, osteomyelodysplasia, AIDS, cancer, and the like.

1,3-benzothiazinone derivatives and use thereof

It is intended to provide a TGR5 receptor agonist containing a fused ring compound represented by the following general formula, its salt or a prodrug thereof: (1) wherein ring A represents an optionally substituted aromatic ring; and the ring B' represents a 5- to 8-membered ring having one or more substituents; which is useful in treating various diseases. 

Receptor agonists

This invention provides a compound represented by the formula (I): wherein Ris a hydrogen atom, a halogen atom, hydroxy, nitro, optionally halogenated alkyl, alkoxy optionally having substituents, acyl or amino optionally having substituents; Ris pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each of which may have substituents; n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I), which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating disease, bone and articular disease, kidney disease, liver disease, osteomyelodysplasia, AIDS, cancer, and the like.

1, 3-benzothiazinone derivatives and use thereof

Growing community of inventors

Osaka, Japan

Taisuke Tawaraishi